Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Many companies have heeded calls from shareholders to tie CEO compensation more closely to performance. As a result, a large ...

NRG's Stock Is a Top Gainer. How Does It Really Make Money? The company looks more like a risky energy trader than a simple power producer. Ethan Allen Faces Fewer Tariffs Than Rivals, but Consumer ...

Paramount Has Offered $15 Million to Settle CBS Lawsuit. Trump Wants More. The president's team threatened another lawsuit amid settlement talks. The AI chip maker's shares rose more than 5% after ...

There’s more than one way to build a portfolio of dividend stocks. The classic move is to buy some individual large-cap ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

Eli Lilly is making waves by acquiring SiteOne Therapeutics for up to $1 billion, eyeing a non-opioid chronic pain treatment.